Mechanically, cisplatin induces dormant and reactivated lung cancer cells, and CTCF governs the entry of cancer cells into dormant states and control the re-entry of dormant cancer cells into the cell cycle.29 Thus, we suspected that CTCF up-regulates PROM2 expression and governs the shift of cellular dormancy and reactivation under cisplatin stimulation, subsequently promotes cell proliferation and inhibits apoptosis, thereby reducing the cisplatin sensitivity. The gene discussed is PROM2; the disease is lung carcinoma.